Stay updated on IGNYTE Study: RP1 Monotherapy and Combo with Nivolumab Clinical Trial
Sign up to get notified when there's something new on the IGNYTE Study: RP1 Monotherapy and Combo with Nivolumab Clinical Trial page.

Latest updates to the IGNYTE Study: RP1 Monotherapy and Combo with Nivolumab Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check20 days agoChange DetectedA new site revision entry v3.3.2 was added to the record history, and the older v3.2.0 entry was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check27 days agoChange DetectedRemoved a government funding notice banner that warned about potential delays in updates and inquiries due to appropriations; no core content or functionality of the study record appears affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check49 days agoChange DetectedThe new screenshot shows only a minor visual/layout adjustment on the Record History page (e.g., spacing and header styling) with the same version list and functionality as the old screenshot. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check70 days agoChange DetectedSignificant update: new operating-status notice and v3.2.0 release; old v3.1.0 tag removed. These changes update core content and versioning with important implications for users.SummaryDifference10%

- Check77 days agoChange DetectedUpdate: version bumped from v3.0.2 to v3.1.0, signifying a newer release.SummaryDifference0.2%

- Check92 days agoChange DetectedPatch version updated from v3.0.1 to v3.0.2; Back to Top element removed.SummaryDifference0.6%

Stay in the know with updates to IGNYTE Study: RP1 Monotherapy and Combo with Nivolumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IGNYTE Study: RP1 Monotherapy and Combo with Nivolumab Clinical Trial page.